z-logo
open-access-imgOpen Access
ABCB 1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy
Author(s) -
Kim HeeJun,
Im SeockAh,
Keam Bhumsuk,
Ham Hye Seon,
Lee Kyung Hun,
Kim Tae Yong,
Kim Yu Jung,
Oh DoYoun,
Kim Jee Hyun,
Han Wonshik,
Jang InJin,
Kim TaeYou,
Park In Ae,
Noh Dong Young
Publication year - 2015
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.12560
Subject(s) - docetaxel , medicine , doxorubicin , breast cancer , chemotherapy , oncology , cancer
Expression of the adenosine triphosphate‐binding cassette B1 ( ABCB 1 ) transporter and P‐glycoprotein are associated with resistance to anticancer drugs. The purpose of this study was to investigate the role of single nucleotide polymorphism in the ABCB 1 and CYP 3A genes in breast cancer patients who were treated with neoadjuvant chemotherapy. Stage II / III breast cancer patients were treated with three cycles of neoadjuvant, after which the patients received curative surgery and adjuvant chemotherapy. The polymorphisms of ABCB 1 and CYP 3A were genotyped. The correlation of polymorphism of ABCB 1 , CYP 3A, and clinical outcomes was analyzed. Among the 216 patients, ABCB 1 3435 TT genotype had a longer overall survival (OS). than CC/CT. Multivariate analyses demonstrated that good PS , invasive ductal carcinoma, non‐triple negative phenotype and initial operable stage were significantly associated with a lower death risk. ABCB 1 3435 TT genotype had a higher AUC than CC / CT for docetaxel. These higher AUC s in the C3435 TT was associated with increased toxicities of neutropenia and diarrhea. This study showed that the genetic polymorphism of ABCB 1 C3435T might be associated with a longer OS . Our results also suggest that the prediction of docetaxel toxicity might be possible for C3435T polymorphism. This study results provides valuable information on individualized therapy according to genotypes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here